We can suggest that the maintenance of ANG (1‐7) levels after aldosterone stimulation could be clinically relevant, indicating that the development of compounds that promote ANG II cleavage to increase ANG (1‐7) levels, yet await clinical trials to be applied to patients with renal disease. This evidence concerns the gene ANGPT1 and kidney disorder.